Toxicity of High-Dose Sequential Chemotherapy and Purged Autologous Hematopoietic Cell Transplantation Precludes Its Use in Refractory/Recurrent Non-Hodgkin's Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 5 A, 2000, Pages 555-562

  Jobnston, Laura J ^a   Stockerl Goldstein, Keith E ^a   Hu, Wendy W ^a   Negrin, Robert S ^a   Hoppe, Richard T ^a   Blume, Karl G ^a   Horning, Sandra J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Autologous hematopoietic cell transplantation; High dose chemotherapy; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; AUTOTRANSPLANTATION; BLEEDING; BONE MARROW DISEASE; BONE MARROW PURGING; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; CYSTITIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIFE TABLE; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PILOT STUDY; SALVAGE THERAPY; STEM CELL MOBILIZATION; SURVIVAL; SURVIVAL RATE; TOXIC HEPATITIS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; BONE MARROW PURGING; CARDIOMYOPATHIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYSTITIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HEPATITIS, TOXIC; HUMANS; INFECTION; KIDNEY FAILURE, ACUTE; LEUCOVORIN; LIFE TABLES; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; METHOTREXATE; MIDDLE AGED; MITOXANTRONE; PILOT PROJECTS; SALVAGE THERAPY; SURVIVAL ANALYSIS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0034571547     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1083-8791(00)70065-6     Document Type: Article

References (13)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
2. Gianni A, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290-1297.
3. Carbone P, Kaplan H, Musshoff K, Smithers D, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
4. Shipp M, Abeloff M, Antman K, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol. 1999;17:423-429.
5. Devine B. Gentamicin. Drug Intell Clin Pharmacol. 1974;8:650-655.
6. Negrin RS, Kusnierz-Glaz CR, Still BJ, et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood. 1995;85:3334-3341.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
8. Stockerl-Goldstein KE, Horning SJ, Negrin RS, et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 1996;2:76-216.
9. Schenkein DP, Roitman D, Miller KB, et al. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 1997;3:210-216.
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
11. Philip T, Gomez F, Guglielmi C, et al. Long-term outcome of relapsed non-Hodgkin's lymphoma patients included in the PARMA trial: incidence of late relapses, long-term toxicity and impact of the international prognostic index at relapse [abstract]. Proc ASCO. 1998;17:16a.
12. Philip T, Armitage J, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316:1493-1498.
13. Vose J, Rowlings P, Lazarus H, Phillips G, Armitage J, Horowitz M. Multivariate analysis of autotransplants for patients with aggressive non-Hodgkin's lymphoma failing primary induction therapy [abstract]. Blood. 1997;90(suppl 1):594a.